A study of gemtuzumab ozogamicin in combination with G-CSF after CAG or MEC (CA-G-GO therapy or MEC-G-GO therapy) for relapsed or refractory acute myeloid leukemia.
Phase 2
- Conditions
- Acute Myeloid Leukemia
- Registration Number
- JPRN-UMIN000027522
- Lead Sponsor
- Wakayama Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1. Pregnant and/or lactating woman 2. History of hematopoietic stem cell transplantation 3. History of interstitial pneumonitis or ARDS 4. History of administration of GO 5. Uncontrolled infection 6. History of veno-occlusive disease 7. History of cardiac dysfunction induced by GO 8. Positive for HBV, HCV and HIV 9. MDS or AML derived from MDS 10. If physicians disagree to attend this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method